HAN Xiao, XU Li, LIU Jian-xun, et al. Yinxing Mihuan Oral Solution Protect HUVECs Against Hypoxia Reoxygenation Injury Through p38 MAPK Regulating eNOS/NO Signaling Pathway[J]. Chinese journal of experimental traditional medical formulae, 2017, 23(23): 79-84.
HAN Xiao, XU Li, LIU Jian-xun, et al. Yinxing Mihuan Oral Solution Protect HUVECs Against Hypoxia Reoxygenation Injury Through p38 MAPK Regulating eNOS/NO Signaling Pathway[J]. Chinese journal of experimental traditional medical formulae, 2017, 23(23): 79-84. DOI: 10.13422/j.cnki.syfjx.2017230079.
Objective: To study the effect and mechanism of Yinxing Mihuan oral solution on human umbilical vein endothelial cells(HUVECs)injured by hypoxia/reoxygenation (H/R) through p38 mitogen activated protein kinase (p38 MAPK) regulating endothelial nitric oxide synthase(eNOS)/nitric oxide (NO) signaling pathway. Method: Hypoxia ischemia/reperfusion injury model was established by hypoxia/hypoglycemia/reoxygenation on HUVECs. Cultured HUVECs were divided into control group
Yinxing Mihuan oral solution high dose +L-NAME. Cell viability and cell injury were measured by cell counting kit-8 (CCK-8) and enzyme labeling method. Protein expression of phosphorylating-p38 MAPK (p-p38 MAPK)/p38 MAPK and phosphorylating-eNOS (p-eNOS)/eNOS were detected by Western blot. The levels of tumor necrosis factor-α (TNF-α)
cysteine aspartate protease-3(Caspase-3)were determined by enzyme-linked immunosorbent assay (ELISA). NO content was measured by nitrate reductase method. Result: Yinxing Mihuan oral solution high and low dose group could significantly improve cell viability and reduce lactate dehydrogenase (LDH) content(P<0.05
P<0.01)
inhibit p-p38 MAPK expression on injured HUVECs
decrease TNF-α
sICAM-1 levels in cell culture supernatant(P<0.05
P<0.01). The inhibited p-eNOS expression was significantly increased after administration of Yinxing Mihuan oral solution high dose and (or) SB203580(P<0.05). Yinxing Mihuan oral solution high dose significantly increased the NO content of damaged HUVECs. After the addition of the eNOS inhibitor L-NAME
Yinxing Mihuan oral solution high dose could antagonize the effects of L-NAME on decreasing NO production and Caspase-3 elevation in injured HUVECs. Conclusion: Yinxing Mihuan oral solution can prevent HUVECs against H/R injury by resisting inflammatory
regulating the endothelial system and inhibiting apoptotic through p38 MAPK regulating eNOS/NO pathway.